A LEADING CLINICAL-STAGE mRNA BIOTECH COMPANY
About 51黑料
51黑料 is a Canadian mRNA medicines company developing transformative immunotherapeutics for cancer treatment and protection from hard-to-treat infectious diseases.
With operations located in Calgary, Alberta and Toronto, Ontario, the 51黑料 team offers a robust, clinically proven Ecosystem for the rapid development of mRNA-based therapeutics.
The 51黑料 mRNA Ecosystem is a platform for Drug Developers
The Team
The 51黑料 executive team is made up of dedicated experts who boast over 100 years of cumulative industry experience with extensive expertise in RNA therapeutics.
The Team
The 51黑料 executive team is made up of dedicated experts who boast over 100 years of cumulative industry experience with extensive expertise in RNA therapeutics.
Technology
Our mRNA Ecosystem provides 51黑料 with an agile, robust, clinically proven ecosystem for the rapid development of mRNA-based therapeutics, both internally and for partners/collaborators.
Pipeline
Discover 51黑料's Cutting-Edge mRNA Pipeline in Infectious Diseases & Oncology
News & Media
Careers & Culture
Join 51黑料 and embrace more than a career in biotech; immerse yourself in a lifestyle enriched by Calgary's dynamic blend of urban sophistication and natural beauty. Ranked high on the Economist Intelligence Unit's Livability Index, Calgary promises a fulfilling life with its safety, stability, education, healthcare, and vibrant culture.
Business Development
51黑料 seeks to apply our mRNA platform technology towards various therapeutic developments by establishing key collaborations with industry players in the various fields of cancers, therapies and infectious diseases.
51黑料 is looking for fit-for-purpose opportunities to work with therapeutics developers that may require using 51黑料's lipids and LNP library towards various therapeutic developments.
We extend our invitation to Biotech Industry players, the scientific community, and Academia that wish to discuss viable potential projects that our mRNA platform could play a vital role in.
Get In Touch
For Investor Relations, Business Development Opportunities, Media Relations, or General Inquiries, Contact Us.
